A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences

References

• Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, Juul S, Nielsen EE, Feinberg JB, Petersen JJ, et al. Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials. PLoS One. 2022;17:e0260733. doi:10.1371/journal.pone.0260733.
   PubMed Web of Science ®Google Scholar
• Farhud DD, Zokaei S. A brief overview of COVID-19 vaccines. Iran J Public Health. 2021;50:i–8. doi:10.18502/ijph.v50i7.6656.
   Web of Science ®Google Scholar
• Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, Kassanjee R, Collie S, Sanne I, Boulle A, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022;399(10330):1141–53. doi:10.1016/S0140-6736(22)00007-1.
   PubMed Web of Science ®Google Scholar
• Massinga Loembé M, Nkengasong JN. COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead. Immunity. 2021;54(7):1353–62. doi:10.1016/j.immuni.2021.06.017.
   PubMed Web of Science ®Google Scholar
• Samarasekera U. Feelings towards COVID-19 vaccination in Africa. Lancet Infect Dis. 2021;21:324–324. doi:10.1016/S1473-3099(21)00082-7.
   PubMed Web of Science ®Google Scholar
• Le Monde. Coronavirus: des spécialistes français s’excusent après leurs propos sur un test de vaccin en Afrique. 2020. https://www.lemonde.fr/afrique/article/2020/04/06/coronavirus-des-specialistes-francais-s-excusent-apres-leurs-propos-sur-un-test-de-vaccin-en-afrique_6035692_3212.html.
   Google Scholar
• Garand M, Cai B, Kollmann TR. Environment impacts innate immune ontogeny. Innate Immun. 2016;23:3–10. doi:10.1177/1753425916671018.
   PubMed Web of Science ®Google Scholar
• Whitworth HS, Kitonsa J, Kasonia K, Tindanbil D, Kafeero P, Bangura J, Nije Y, Tetsa Teta D, Greenwood B, Kavunga-Membo H, et al. COVID-19 vaccine acceptability among healthcare facility workers in Sierra Leone, the democratic Republic of Congo and Uganda: a multi-centre cross-sectional survey. Int J Public Health. 2022;67:1605113. doi:10.3389/ijph.2022.1605113.
   PubMed Web of Science ®Google Scholar
• Rappaport AR, Hong S-J, Scallan CD, Gitlin L, Akoopie A, Boucher GR, Egorova M, Espinosa JA, Fidanza M, Kachura MA, et al. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nat Commun. 2022;13:3289. doi:10.1038/s41467-022-31005-z.
   PubMed Web of Science ®Google Scholar
• Maruggi G, Mallett CP, Westerbeck JW, Chen T, Lofano G, Friedrich K, Qu L, Sun JT, McAuliffe J, Kanitkar A, et al. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Mol Ther. 2022;30:1897–912. doi:10.1016/j.ymthe.2022.01.001.
   PubMed Web of Science ®Google Scholar
• Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, O’Hara J, McFarlane LR, Lemm NM, et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. EClinicalMedicine. 2022;44:101262. doi:10.1016/j.eclinm.2021.101262.
   PubMedGoogle Scholar
• FDA. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. Rockville, USA: U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. http://www.fda.gov/cber/guidelines.htm
   Google Scholar
• Lutalo T, Nalumansi A, Olara D, Kayiwa J, Ogwang B, Odwilo E, Watera C, Balinandi S, Kiconco J, Nakaseegu J, et al. Evaluation of the performance of 25 SARS-CoV-2 serological rapid diagnostic tests using a reference panel of plasma specimens at the Uganda virus research institute. Int J Infect Dis. 2021;112:281–7. doi:10.1016/j.ijid.2021.09.020.
   PubMed Web of Science ®Google Scholar
• Garand M, Cai B, Kollmann TR. Environment impacts innate immune ontogeny. Innate Immun. 2017;23(1):3–10. doi:10.1177/1753425916671018.
   PubMed Web of Science ®Google Scholar
• Nkurunungi G, Zirimenya L, Natukunda A, Nassuuna J, Oduru G, Ninsiima C, Zziwa C, Akello F, Kizindo R, Akello M, et al. Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics. BMJ Open. 2020;11(2):e040425. doi:10.1136/bmjopen-2020-040425.
   Web of Science ®Google Scholar
• Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: implications for COVID-19 vaccines. J Med Virol. 2022;94(4):1330–5. doi:10.1002/jmv.27485.
   PubMed Web of Science ®Google Scholar
• Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, Tambyah PA, Blumberg L, Yapi R, Al-Abri S, et al. Emergence of new SARS-CoV-2 variant of concern omicron (B.1.1.529) - highlights Africa’s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2022;114:268–72. doi:10.1016/j.ijid.2021.11.040.
   PubMed Web of Science ®Google Scholar
• Guleid FH, Oyando R, Kabia E, Mumbi A, Akech S, Barasa E. A bibliometric analysis of COVID-19 research in Africa. BMJ Glob Health. 2021;6(5):e005690. doi:10.1136/bmjgh-2021-005690.
   PubMed Web of Science ®Google Scholar
• Bryce E, Ong S. Covid-19 and mRNA technology are helping Africa fix its vaccine problems. Bmj. 2022;377:o1196. doi:10.1136/bmj.o1196.
   PubMedGoogle Scholar
• Ndejjo R, Chen N, Kabwama SN, Namale A, Wafula ST, Wanyana I, Kizito S, Kiwanuka SN, Sambisa W, Tsai LL, et al. Uptake of COVID-19 vaccines and associated factors among adults in Uganda: a cross-sectional survey. BMJ Open. 2023;13(3):e067377. doi:10.1136/bmjopen-2022-067377.
   PubMed Web of Science ®Google Scholar
• He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 omicron variant: characteristics and prevention. MedComm. 2021;2(4):838–45. doi:10.1002/mco2.110.
   PubMedGoogle Scholar
• Bbosa N, Ssemwanga D, Namagembe H, Kiiza R, Kiconco J, Kayiwa J, Lutalo T, Lutwama J, Ssekagiri A, Ssewanyana I, et al. Rapid replacement of SARS-CoV-2 variants by delta and subsequent arrival of Omicron, Uganda, 2021. Emerg Infect Dis. 2022;28(5):1021–5. doi:10.3201/eid2805.220121.
   PubMed Web of Science ®Google Scholar
• Li B, Zhang Q, Liu Y, Zhang X, Cheng D, Li A, Chen Y, Zhu X, Su Y, Zhou H. Analysis of the reasons for screening failure in phase I clinical trials in China: a retrospective study of the clinical trials screening process. Ann Transl Med. 2021;9(20):1564. doi:10.21037/atm-21-5010.
   PubMed Web of Science ®Google Scholar
• Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, Tumusiime R, Wandege J, Sanya R, Sateren WB, Wabwire-Mangen F, et al. Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS One. 2008;3(12):e3919. doi:10.1371/journal.pone.0003919.
   PubMed Web of Science ®Google Scholar